1. What to say and how to say it: effective communication for cardiovascular disease prevention.

    Current Opinion in Cardiology 31(5):537 (2016) PMID 27428113

    Current guidelines for cholesterol treatment emphasize the importance of engaging patients in a risk-benefit discussion prior to initiating statin therapy. Although current risk prediction algorithms are well defined, there is less data on how to communicate with patients about cardiovascular di...
  2. The ABCDs of Lifestyle Counseling.

    JAMA Cardiology 1(5):505 (2016) PMID 27439176

  3. Patients and Physicians Beliefs and Practices Regarding Adherence to Cardiovascular Medication.

    JAMA Cardiology 1(4):470 (2016) PMID 27438324

    Nonadherence to medication is a salient cause of poor outcomes of health care and a primary driver of growing health care costs. Little is known about physician communication with patients regarding their adherence to cardioprotective medication. To identify patients' and physicians' beliefs and...
  4. Advances in Lipid Testing: A Practical Step Forward.

    Clinical Chemistry 62(7):905 (2016) PMID 27197679

  5. The Pooled Cohort Equations for Predicting Risk of Myocardial Infarction and Stroke: Validated in Representative Natural History Populations.

    Mayo Clinic Proceedings 91(6):692 (2016) PMID 27180123

  6. Shared Decision-Making and Patient Empowerment in Preventive Cardiology.

    Current Cardiology Reports 18(5):49 (2016) PMID 27098670

    Shared decision-making, central to evidence-based medicine and good patient care, begins and ends with the patient. It is the process by which a clinician and a patient jointly make a health decision after discussing options, potential benefits and harms, and considering the patient's values and...
  7. Author's Reply.

    Clinical Cardiology (Hoboken) 39(5):307 (2016) PMID 27217057

  8. New Strategies to Treat High Cholesterol.

    JAMA 315(11):1169 (2016) PMID 26978218

  9. Fasting or Nonfasting Lipid Measurements: It Depends on the Question.

    Journal of the American College of Cardiology 67(10):1227 (2016) PMID 26965545

    In the 2013 American College of Cardiology (ACC)/American Heart Association Guideline (AHA) on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, low-density lipoprotein cholesterol treatment thresholds have been replaced with a focus on global risk. In t...
  10. Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?

    Clinical Chemistry 62(3):428 (2016) PMID 26787760

  11. Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies.

    World Journal of Cardiology 8(2):201 (2016) PMID 26981215 PMCID PMC4766270

    Cardiovascular disease is the leading cause of death in the United States. In 2010, the Centers for Disease Control and Prevention estimated that $444 billion was spent on cardiovascular diseases alone, about $1 of every $6 spent on health care. As life expectancy continues to increase, this ann...
  12. The ASCVD Risk Estimator App: From Concept to the Current State.

    Journal of the American College of Cardiology 67(3):350 (2016) PMID 26796407

  13. Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease.

    Annals of Internal Medicine 164(2):135 (2016) PMID 26784486

  14. Getting What the Guidelines Stated Matters.

    Journal of the American College of Cardiology 67(1):119 (2016) PMID 26764076

  15. Statin therapy across the lifespan: evidence in major age groups.

    Expert Review of Cardiovascular Therapy 14(3):341 (2016) PMID 26641725

    This review provides needed perspective on statin efficacy and safety in individuals under 40, 40-75, and > 75 years of age. Starting with the 2013 ACC-AHA cholesterol guidelines extensive evidence base on randomized controlled trials (RCTs) we added references in the past 5 years that discussed...
  16. MY APPROACH to cardiovascular risk assessment to reduce atherosclerotic risk.

    Trends in Cardiovascular Medicine 26(1):92 (2016) PMID 26632015

  17. Statin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease.

    Clinical Cardiology (Hoboken) 39(1):41 (2016) PMID 26695111

    No medical therapy has been proven to prevent the progression of aortic dilatation in bicuspid aortic valve (BAV) disease, and prophylactic aortic surgery remains the mainstay of treatment. Among patients with BAV disease who are referred for surgery, preoperative statin use is associated with d...
  18. Statins and Nonadherence: Should We RELATE Better?

    Journal of Cardiovascular Pharmacology and Ther... 20(5):447 (2015) PMID 25827856

    Statin nonadherence is a major challenge to optimal management. Patients nonadherent to statin therapy do not receive the expected benefit relative to the degree of low-density lipoprotein cholesterol (LDL-C) lowering obtained. This is important because new evidence guidelines recommend statins ...
  19. Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts.

    The American Journal of Cardiology 116(3):481 (2015) PMID 26043952

    Familial hypercholesterolemia (FH) is a genetic condition resulting in severe, lifelong elevations in low-density lipoprotein cholesterol and a marked increased risk of early-onset coronary disease. FH is treatable when identified, yet is vastly under-recognized and undertreated. Although the 20...
  20. Primary risk prevention in the elderly: use clinician-patient discussions, not automatic statin prescribing.

    The American Journal of Medicine 128(8):804 (2015) PMID 25820167